| Literature DB >> 35705691 |
Bushra Hafeez Kiani1, Fizza Ikram2, Humaira Fatima3, Aiyeshah Alhodaib4, Ihsan-Ul- Haq3, Tofeeq Ur-Rehman3, Iffat Naz5.
Abstract
The use of the green approach for nanoparticle synthesis yielded noticeable concern due to its eco-friendliness, cost-effectiveness, and reduced production of toxic chemicals. The current study was designed to formulate Zinc oxide nanoparticles (ZnO NPs) by using Fagonia cretica extracts, evaluating its phytochemical content, and different biological activities. Four different solvents; methanol (MeOH), n-Hexane (n-H), aqueous (Aq), and ethyl acetate (EA), had been utilized in the extracting method. ZnO NPs were successfully synthesized and characterized by UV-vis spectroscopy and scanning electron microscopy (SEM). The UV-vis spectra showed absorbance peaks between 350-400 nm range and SEM analysis revealed spherical morphology with particle sizes ranging from 65-80 nm. In phytochemical analysis, crude extracts exhibited the highest phytochemical content as they contain enriched secondary metabolites. n-hexane extract showed the highest phenolic contents while aqueous extracts showed the highest flavonoid content. Maximum free radicle scavenging activity was observed in NPs synthesized from ethyl-acetate extract with an IC50 value of 35.10 µg/ml. Significant antibacterial activity was exhibited by NPs polar solvents against K. pneumonae, E. coli, and B. subtilis. Polar solvents showed considerable antifungal potential against A. flavus and F. solani. NPs synthesized from nH extract showed potential cytotoxic activity with an LC50 value of 42.41 µg/ml against brine shrimps. A noteworthy antidiabetic activity was exhibited by nanoparticles synthesized from methanol extract i.e., 52.61 ± 0.36%. Significant bald zones were observed in nanoparticles synthesized from methanol extract rendering protein kinase inhibition. The present study highlights the significance of F. indica as a natural source for synthesizing functional nanoparticles with substantial antioxidant, antimicrobial, cytotoxic, protein kinase inhibitory, and antidiabetic properties.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35705691 PMCID: PMC9200713 DOI: 10.1038/s41598-022-14193-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Extract recovery of Fagonia cretica samples.
| S. No | Extract codes | Dielectric constant at 25 °C | Percent extract recovery % (w/w) |
|---|---|---|---|
| 1 | nH | 1.88 | 1.90 |
| 2 | EA | 6.02 | 5.07 |
| 3 | M | 32.70 | 11.95 |
| 4 | Aq | 78.20 | 18.49 |
*nH n-Hexane, EA Ethyl Acetate, M Methanol, Aq Aqueous.
Figure 1UV Visible absorption spectra of zinc oxide nanoparticles. (A) n-Hexane (B) Ethyl Acetate (C) Methanol (D) Aqueous.
Figure 2SEM images of zinc oxide nanoparticles. (A) n-Hexane (B) Ethyl Acetate (C) Methanol (D) Aqueous.
Figure 3Total phenolic content of F.cretica crude extracts and its synthesized ZnO NPs. Values given are expressed as the mean of triplicate ± standard deviation.
Figure 4Total flavonoid content of F.cretica crude extracts and its synthesized ZnO NP. Values given are expressed as the mean of triplicate ± standard deviation.
Figure 5Comparative analysis of the antioxidant activity of ZnO NPs and crude extracts of F. cretica. Values given are expressed as the mean of triplicate ± standard deviation.
Antibacterial activity and MIC values of F. cretica crude extracts and ZnO NPs.
| Extract codes | Antibacterial assay | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Diameter of zone of inhibition in mm (Mean ± SD) (MIC: µg/ml) | ||||||||||
| S.A | MIC | K.P | MIC | P.A | MIC | E.C | MIC | B.S | MIC | |
| nH | 7 ± 0.21 | – | 10 ± 0.25 | – | 5 ± 0.37 | – | 11 ± 0.17 | – | 7 ± 0.22 | – |
| EA | 7 ± 0.32 | – | 7 ± 0.17 | – | 5 ± 0.43 | – | 7 ± 0.21 | – | 6 ± 0.31 | – |
| M | 6 ± 0.25 | – | 14 ± 0.31 | 100 | 7 ± 0.21 | – | 12 ± 0.25 | 100 | 12 ± 0.17 | 100 |
| Aq | 8 ± 0.36 | – | 9 ± 0.27 | – | 6 ± 0.19 | – | 10 ± 0.28 | – | 13 ± 0.27 | 100 |
| nH | 10 ± 0.19 | – | 12 ± 0.25 | 100 | 6 ± 0.21 | – | 12 ± 0.17 | 100 | 9 ± 0.22 | – |
| EA | 5 ± 0.36 | – | 9 ± 0.18 | – | 6 ± 0.37 | – | 7 ± 0.21 | – | 12 ± 0.31 | 100 |
| M | 9 ± 0.25 | – | 18 ± 0.19 | 33.3 | 9 ± 0.25 | – | 16 ± 0.23 | 100 | 21 ± 0.40 | 3.7 |
| Aq | 7 ± 0.32 | – | 15 ± 0.28 | 100 | 8 ± 0.19 | – | 8 ± 0.28 | – | 13 ± 0.19 | 100 |
| DMSO | – | – | – | – | – | – | – | – | – | – |
*The sample concentration was 100 µg per disc. Values (mean ± SD) are average of triplicate analysis of each plant extract (n value of 1 × 3). – = No activity. Samples showing zone of inhibition ≤ 12 mm were not proceeded for MIC determination. . S.A = Staphylococcus aureus, B.S = Bacillus subtilis, P.A = Pseudomonas aeruginosa, K. P = Klebsiella pneumoniae, E.C = Escherichia coli. . Positive control = Cef: Cefaxime, Rox: Roxithromycin. –- = no activity.
Figure 6Antibacterial activity of F. cretica (A) Nanoparticles (B) Crude Extracts.
Antifungal activity of F.cretica crude extracts and its ZnO nanoparticles.
| Plant name | Extract name | Sample | Antifungal activity | |||
|---|---|---|---|---|---|---|
| Zone of inhibition (mm ± SD) | ||||||
| nH | NP | 7 ± 0.19 | – | – | 7 ± 0.25 | |
| C | – | –– | – | – | ||
| EA | NP | – | – | – | – | |
| C | – | – | – | – | ||
| M | NP | 15 ± 0.40 | – | – | 12 ± 0.31 | |
| C | 11 ± 0.21 | – | – | 6 ± 0.11 | ||
| Aq | NP | 13 ± 0.27 | – | – | 9 ± 0.19 | |
| C | – | – | – | 8 ± 0.21 | ||
| Control | Clot– | 20 ± 0.57 | 20 ± 0.9 | 21 ± 0.57 | 22 ± 1.23 | |
*DMSO = negative control. –- = no activity. Clot = clotrimazole.
Values (mean ± SD) are average of triplicate of each test sample (n value of 1 × 3).
Brine shrimp lethality potential of F.cretica crude extracts and its ZnO nanoparticles.
| Plant name | Extracts | Samples | Percent mortality (%) | LC50 (µg/ml) | ||
|---|---|---|---|---|---|---|
| 200 | 100 | 50 | ||||
| nH | NP | 100 ± 1.50 | 100 ± 1.50 | 60 ± 1.0 | 42.41 | |
| C | 100 ± 1.50 | 100 ± 1.50 | 50 ± 1.40 | 44.52 | ||
| EA | NP | 80 ± 1.25 | 70 ± 1.25 | 50 ± 1.70 | 62.45 | |
| C | 70 ± 1.15 | 60 ± 1.25 | 40 ± 1.0 | 72.92 | ||
| M | NP | 60 ± 1.25 | 20 ± 1.60 | 10 ± 1.40 | 140.6 | |
| C | 40 ± 0.85 | 20 ± 1.0 | – | ˃200 | ||
| Aq | NP | 20 ± 1.75 | 20 ± 1.50 | – | ˃200 | |
| C | 20 ± 1.75 | 10 ± 1.50 | ˃200 | |||
* Values given are expressed as a mean of triplicate ± SD. Positive control = Doxorubicin (5.93ug/ml). Negative control = DMSO.
* LC50 of positive control (Doxorubicin) was 5.93 µg/ml. DMSO was applied as negative control and the values given are expressed as a mean of triplicate ± SD.
Figure 7Protein kinase inhibition activity of F. cretica crude extracts and its ZnO nanoparticles. α-Amylase inhibition activity.
Protein kinase inhibition potential of F. cretica crude extracts and its ZnO nanoparticles.
| Plant name | Extract name | Samples | Zones | Activity |
|---|---|---|---|---|
| nH | NP | 9 | Bald | |
| C | 6 | Clear | ||
| EA | NP | 9 | Bald | |
| C | 5 | NA | ||
| M | NP | 15 | Bald | |
| C | 10 | Bald | ||
| Aq | NP | 11 | Bald | |
| C | 7 | Clear |
*DMSO negative control, Surfactin positive control (20 µg/disc; 16 mm zone – = No activity.
Figure 8α-amylase inhibition potential of F. cretica crude extracts and its ZnO nanoparticles. Values given are expressed as the mean of triplicate ± standard deviation.